What Is Miebo and Does It Work for Dry Eyes?
Miebo (perfluorohexyloctane ophthalmic solution) is an FDA-approved eye drop for treating dry eye disease (DED) in adults. It targets the signs and symptoms of DED by forming a protective layer on the eye surface to reduce tear evaporation, unlike traditional drops that add moisture.[1] Clinical trials showed it reduces tear evaporation by about 60-70% and improves symptoms like eye discomfort and dryness within two weeks of twice-daily use.[2]
How Does Miebo Work in the Eye?
Miebo is a water-free, preservative-free drop that spreads across the aqueous tear layer, sealing it to prevent evaporation. This addresses meibomian gland dysfunction, a common DED cause where oil glands fail to produce enough lipid for tears. Patients report faster symptom relief compared to some other drops, with effects lasting up to four hours per dose.[1][3]
Miebo Clinical Trial Results
Two Phase 3 trials (GOBUFA-1 and GOBUFA-2) involved over 1,200 patients. Key findings:
- 53-58% of Miebo users had no or minimal eye discomfort after six weeks, versus 41-46% on vehicle.[2]
- Total corneal fluorescein staining (a dryness damage measure) improved by 1.3-1.5 points on a 4-point scale.[2]
The FDA approved it in May 2023 based on these results, confirming efficacy for DED signs and symptoms.[1]
Who Is Miebo For and Common Patient Experiences?
It's indicated for anyone 18+ with dry eyes, especially evaporative DED. Patients often ask if it works for contact lens wearers—it does, but remove lenses before use. Real-world feedback notes less burning on application than watery drops, though some experience temporary blurred vision.[3][4] Not for allergies to its ingredients.
Miebo vs. Other Dry Eye Treatments
| Treatment | Mechanism | Dosing | Key Difference from Miebo |
|-----------|-----------|--------|---------------------------|
| Restasis (cyclosporine) | Reduces inflammation | Twice daily | Takes 4-6 months; prescription |
| Xiidra (lifitegrast) | Blocks inflammation proteins | Twice daily | Faster relief but more stinging |
| Systane/Uptime (OTC) | Adds artificial tears | As needed | Temporary hydration; no evaporation barrier |
| Tyrvaya (varenicline) | Stimulates natural tears | Once daily nasal spray | Non-eye drop option |
Miebo stands out for its lipid-based evaporation protection, working alongside other therapies.[3]
Side Effects and When It Might Not Work
Most common: blurred vision (13%), eye redness (5%), and pain (5%). Rare serious issues include eye infections if contaminated. It may not fully resolve severe inflammation-driven DED—combine with anti-inflammatories if needed. Consult an eye doctor if symptoms persist after two weeks.[1][4]
Cost, Availability, and Patent Status
Miebo costs $700-900 for a 30-day supply without insurance; patient assistance programs cap copays at $25.[5] Manufactured by Bausch + Lomb and Novaliq. U.S. patents extend to 2041, with no generics until then—check DrugPatentWatch.com for updates.[6]
[1]: FDA Label - Miebo ( MieboPI.pdf)
[2]: New England Journal of Medicine - Phase 3 Trials (2023)
[3]: Bausch + Lomb prescribing info
[4]: American Academy of Ophthalmology patient guide
[5]: GoodRx pricing data
[6]: DrugPatentWatch.com - Miebo patents